Top 2 S&P 500 Stocks to Watch This Week After Hims & Hers Stock's Surprise Move

Hims & Hers ended its lawsuit with Novo Nordisk and struck a deal, helping HIMS rally ~50% in March despite being ~65% below its highs. The piece highlights that weight‑loss drugmakers—chiefly Novo Nordisk (NVO) and Eli Lilly (LLY)—control the market economics, with both firms' revenues up ~200% over the past 10 years and net income north of $15 billion annually. Hims & Hers remains barely profitable as a reseller, so most profits accrue to the drugmakers; monitor NVO and LLY as the sector leaders likely to drive sustained momentum in the weight‑loss category.

Analysis

The recent channel deals accelerate a structural bifurcation: molecule owners will monetize through price and access levers while front‑end telehealth channels compete for thin, recurring referral economics. Expect telehealth players to invest in customer LTV (subscription bundles, cross‑sell) rather than drug margin capture; that shift will favor platforms with large, sticky customer bases and raise M&A pressure among smaller resellers within 12–24 months.

Second‑order winners include specialty distributors and PBMs that can control fulfillment flow and data (they become the gatekeepers for adherence and reimbursement programs); losers are commoditized telehealth intermediaries without differentiated patient engagement tools. A sustained supply tightness or prioritization by manufacturers could keep wholesale channels captive to manufacturer pricing strategies, compressing reseller gross margins by an estimated mid‑single digits over the next year unless resellers add high‑margin services.

Key risks and catalysts: near‑term demand volatility from seasonal prescriptions and inventory lags (days–months), mid‑term payer decisions on formulary and coverage (6–18 months) and long‑term pricing pressure from biosimilars/generic entrants (2–5 years). A regulatory or payer push to restrict off‑label distribution or tighten prescribing guardrails would be the fastest path to unwind the current channel mix; conversely, rapid payer coverage expansion would reconfigure who captures value (manufacturers vs payers) rather than eliminate the category growth story.

Key Decisions for Investors

• Pair trade (6–12 months): Long LLY / Short HIMS equal dollar. Thesis: capture durable manufacturer upside vs compressed reseller margins. Target: 25–35% asymmetric upside if LLY outperforms by >20%; stop if LLY underperforms HIMS by >10% within 3 months.
• Options trade (9–12 months): Buy LLY 9–12 month call spread sized to 3–5% of equity book. R/R: ~2–3x if uptake momentum continues and consensus EPS moves up; deltas limited to preserve capital if regulatory headlines compress sector multiples.
• Event-driven short (3–6 months): Buy HIMS puts or short HIMS into any post‑deal pop with a tight stop. Thesis: limited margin capture and customer acquisition costs will pressure cashflow; target 30–40% downside to pre‑deal sentiment levels, stop at +15% from entry.
• Relative defensive (12–24 months): Accumulate NVO on pullbacks versus LLY as a hedge to execution volatility. Use sizing to cap single‑name exposure to 4–6% of biotech book; reward is stable cash generation if GLP‑1 pricing normalizes, risk is competitive share loss to LLY.